Floatz logo

Gm-K562/Leukemia Cell Vaccine

Chronic Myelomonocytic Leukemia

Dana-Farber Cancer InstitutevaccinePhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
73/ 100

Competitive context

83 Active assets in the Chronic Myelomonocytic Leukemia cohort.

Asset / SponsorPhaseRating
Venetoclax
Servier Bio-Innovation LLC
Phase 2/3BB
Azacitidine
The University of Hong Kong
Phase 3BB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2BB
Astx727
Taiho Oncology, Inc.
Phase 3BB
Evomela
City of Hope Medical Center
Phase 2BB

View all 50 →

Same molecule, other indications

Gm-K562/Leukemia Cell Vaccine is also rated in:

Myelodysplastic Syndrome-Refractory Anemia With Excess BlastsDormant
CC
Indicative ·
47 / 100
View asset →
Acute Myeloid LeukemiaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →